Skip to main content

Health

Sanofi Shines in Q3 2024 with Strong Growth and Innovation

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development. Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

Sanofi Takes a Stand: Removing the Stigma of Cancer in the Workplace

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues. "We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

Upskilling Professionals for Sustainable Healthcare in Tanzania

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens. A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.

Abbott and Big Ten Conference Tackle Blood Shortage with "The We Give Blood Drive"

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 07, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game. The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 07, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

GE HealthCare Expected to Report Revenue and Profit Growth Despite Economic Headwinds

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 07, 2024 – GE HealthCare, a leading global medical technology and diagnostics company, is poised to announce its latest quarterly earnings before the market opens on Wednesday. Financial analysts are predicting an increase in both revenue and profits compared to the same period last year, signaling continued resilience amidst a challenging global economic landscape.

Roche Opens New Pharma Research and Early Development Center in Basel

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 07, 2024-Roche (SIX: RO, ROG; OTCQX: RHHBY) has opened its new Pharma Research and Early Development Center (pRED) at its global headquarters in Basel. The center has 1,800 laboratory and office workplaces, bringing together researchers from different disciplines, explains Roche in a statement. The center’s inauguration was attended by Federal Councillor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research.

Roche Showcases Promising Lymphoma Advancements at ASH 2024

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 07, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.

Roche Reports Strong Sales Growth in the Third Quarter of 2024

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 7, 2024 – Roche, a global healthcare pioneer, has announced continued strong sales growth in the third quarter of 2024. The company's performance was driven by high demand for both its Pharmaceuticals and Diagnostics divisions, with Group sales increasing by 9% at constant exchange rates (CER). [cite: 1, 2, 3] “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world,” said Roche CEO Thomas Schinecker. Pharmaceuticals Division

Experience the Pinnacle of Pilates with the Infinity Reformer: Unparalleled Quality and Versatility for Every Body

Submitted by newsonline24.c… on
SHERIDAN, WYOMING – November 06, 2024– Elevate your Pilates practice with the Infinity Reformer, a revolutionary apparatus crafted with unparalleled quality and designed for ultimate versatility. As the only reformer on the market constructed from Lyptus® FAS – the highest quality wood with reforestation certification – the Infinity Reformer provides a stable and elegant foundation for precise and effective Pilates workouts. Whether you're a seasoned Pilates enthusiast, a patient in physical therapy, or a high-performance athlete, the Infinity Reformer adapts to your needs and goals. With the ability to perform over 200 exercises, this exceptional piece of equipment empowers you to strengthen your core, improve flexibility, and enhance overall well-being.